Ligand Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with a platform license agreement with Fred Hutchinson Cancer Research Center for use of OmniAb platform transgenic rodents to generate and discover human antibodies.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.